Granisetron transdermal - Acrux

Drug Profile

Granisetron transdermal - Acrux

Alternative Names: Granisetron MDTS®

Latest Information Update: 14 Jun 2007

Price : $50

At a glance

  • Originator Acrux
  • Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
  • Mechanism of Action Serotonin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Nausea and vomiting

Most Recent Events

  • 02 Jul 2004 Phase-I clinical trials in Nausea and Vomiting in Australia (Transdermal)
  • 02 Jul 2004 Transdermal granisetron is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top